Evidence map›Paper›PMID 26012380›Full record

ArticleJournal of nephrology2016

Peritoneal Cell-free DNA: an innovative method for determining acute cell damage in peritoneal membrane and for monitoring the recovery process after peritonitis.

Grazia Maria Virzì, Sabrina Milan Manani, Alessandra Brocca, Vincenzo Cantaluppi, Massimo de Cal, Silvia Pastori, Ilaria Tantillo, Roberto Zambon, Carlo Crepaldi, Claudio Ronco

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Technical and Methodological Aspects of Cell-Free Nucleic Acids Analyzes.International journal of molecular sciences · 2020
    Review
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Grazia Maria VirzìIRRIV-International Renal Research Institute Vicenza, Vicenza, Italy. graziamaria.virzi@gmail.com.
Sabrina Milan MananiIRRIV-International Renal Research Institute Vicenza, Vicenza, Italy.
Alessandra BroccaIRRIV-International Renal Research Institute Vicenza, Vicenza, Italy.
Vincenzo CantaluppiNephrology, Dialysis and Kidney Transplantation Unit, Department of Medical Sciences, Azienda Ospedaliera "Città della Salute e della Scienza di Torino- Presidio Molinette", University of Turin, Turin, Italy.
Massimo de CalIRRIV-International Renal Research Institute Vicenza, Vicenza, Italy.
Silvia PastoriIRRIV-International Renal Research Institute Vicenza, Vicenza, Italy.
Ilaria TantilloIRRIV-International Renal Research Institute Vicenza, Vicenza, Italy.
Roberto ZambonDepartment of Nephrology, Dialysis and Transplant, San Bortolo Hospital, Via Rodolfi, 37 - 36100, Vicenza, Italy.
Carlo CrepaldiIRRIV-International Renal Research Institute Vicenza, Vicenza, Italy.
Claudio RoncoIRRIV-International Renal Research Institute Vicenza, Vicenza, Italy.
Ospedale San Bortolo · ITInternational Renal Research Institute of Vicenza · ITUniversity of Padua · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCell-free DNA (cfDNA) is present in the peritoneal effluent of stable peritoneal dialysis (PD) patients, but there are no data on cfDNA in PD patients with peritonitis. We investigated the variation of peritoneal cfDNA levels subsequent to peritonitis in PD patients.

methodsWe enrolled 53 PD patients: 30 without any history of systemic inflammation or peritonitis in the last 3 months (group A) and 23 with acute peritonitis (group B). CfDNA was quantified in the peritoneal effluent. Peritoneal samples on days 1, 3, 10, 30 and until day 120 from the start of peritonitis were collected for white blood cells (WBC) count and cfDNA evaluation in group B.

resultsQuantitative analysis of cfDNA showed significantly higher levels in group B on day 1, 3, 10 and 30 compared with group A (p < 0.05). A significant positive correlation was observed between cfDNA concentration and WBC on day 1 (rho = 0.89) and day 3 (rho = 0.5) (both, p < 0.05). However, no significant correlation was observed between cfDNA and WBC on days 10 and 30. In group B, peritoneal cfDNA levels tended to progressively decline during follow-up of peritonitis. From this decreasing curve, we estimated that 49 days are necessary to reach the value of 51 genome equivalents (GE)/ml (75th percentile in controls) and 63 days to reach 31 GE/ml (median).

conclusionOur results demonstrate that cfDNA increases in peritoneal effluent of PD patients with peritonitis and tends to progressively decline in step with peritonitis resolution and membrane repair process. Peritoneal cfDNA quantification could be an innovative method to determine acute damage and an inverse index of the repair process.

Indexed as

Real-Time Polymerase Chain ReactionAcute DiseaseAgedAged, 80 and overApoptosisAscitic FluidCross-Sectional StudiesDNAFemaleGenetic MarkersHumansKidney Failure, ChronicLeukocyte CountMaleMiddle AgedPeritoneal DialysisDNAGenetic MarkersCell free DNAPeritoneal dialysisPeritoneal membranePeritonitisRecovery process

Identifiers

PMID26012380
OpenAlexW420705781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.